Alfacell Corporation (OTCPK: ACEL ) Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases.

        The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technologies, knowledge, experience, and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

For a description of our material agreements relating to our strategic collaborations and research arrangements and other material agreements, please refer to “Item 4.B. Information on the Company—Business Overview—Strategic Collaborations, Research Arrangements and other Material Agreements.”

The obtained hearts were fixed in 4% paraformaldehyde solution for 48 hours, and processed for paraffin section (5 μm). Sections were stained with HE, WGA and rhodamine phalloidine. The sections were observed with microscope (BX512DP70, Olympus, Tokyo, Japan) or laser scanning confocal microscope (TCS SP5, Leica, Mannheim, Germany), and five fields were randomly selected for evaluation. Cardiomyocyte cross section area was determined on sections stained with WGA in randomly selected 5 fields, calculating the average of cross section areas of 3–5 cells in each, using Image-Pro Plus 6.0 (Media Cybernetic, Bethesda, MD, USA).

The SPSS version 18.0 (Chicago, IL, USA) software was used in the statistical analysis. The data were expressed as means ± SD and p < 0.05 was considered statistically significant. Tukey was used to determine differences between groups.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

“We’re continuing to investigate and take action to protect patient health and safety from products in this angiotensin II receptor blocker class that have been found to have dangerous impurities. As part of that investigation, we’ve uncovered serious manufacturing violations at ZHP, which is one of the manufacturing facilities that has been linked to these products. The issues cited in the warning letter are associated with the nitrosamine impurities found in these drugs, and these violations reveal a disturbing lack of oversight at this API manufacturer that puts patients at risk,” said FDA Commissioner Scott Gottlieb, in a press statement announcing the warning letter.

Rat myocardium from each group was examined by microscopy using hematoxylin and eosin (HE) and F-actin staining. As noticed in Fig. 3a, AAS led to tissue edema, myocardial fiber thickening and F-actin rupture, which were more prominent in AAS2M than in AAS1M. Clearly, these AAS-induced morphological alterations in myocardium were attenuated in the rats received all drug treatments except DO. Particularly, QSYQ and the combination treatments were more effective in relieving these alterations than any mono-therapy.

BC Residents and Investor Disclaimer : Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Wang, C. J. et al. The effects of shockwave on bone healing and systemic concentrations of nitric oxide (NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions. Nitric Oxide 20, 298–303 (2009).

Activation of hypoxia-inducible factor 1α (HIF-1α) is the primary hypoxia-driven signaling pathway in the pulmonary vasculature10,11. HIF-1α is a heterodimeric transcription factor that is composed of a regulatory α subunit and a constitutive β subunit (HIF-1β/ARNT). HIF-1α is selectively stabilized under hypoxia, so it can translocate into the nucleus to combine with the β subunit and bind to the hypoxia responsive elements (HREs) and activate transcription of genes that promote vascular cell growth and development, glycolytic metabolism and cell cycle events12. In heterozygous HIF-1α knockout mice, hypoxia-induced pulmonary hypertension and vascular remodeling are notably reduced13. Also, HIF-2α heterozygous deficient mice do not develop pulmonary hypertension even after exposure to prolonged hypoxia14. However, the key molecular and cellular pathways that are influenced by HIF are still being described.

NK cells were added to 4 × 105 B16F10 cells in 200 μl complete medium. Cells were incubated for 30 min at 37°C in a 5% CO2 incubator. Thereafter, supernatants were collected and cytokines were assayed with ELIZA kits from eBioscience (granzyme B) according to the instructions of the manufacturer.